Emicizumab biosimilar - Prestige BioPharma
Alternative Names: IDC-2301Latest Information Update: 10 Oct 2024
At a glance
- Originator Prestige BioPharma
- Class Antihaemorrhagics; Bispecific antibodies; Recombinant proteins
- Mechanism of Action Factor IXa stimulants; Factor X stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Haematological disorders
Most Recent Events
- 10 Sep 2024 Early research in Haematological disorders in Singapore (Parenteral) before September 2024 (Prestige BioPharma pipeline, September 2024)